PYC Therapeutics: Notice of Annual General Meeting/Proxy Form
Filed with ASX · · 17 pages · English
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- FDA Grants Rare Pediatric Disease Designation to PYC-001
- Appendix 4E and Audited Financial Statements
- PYC to Start Human Trials in Second Blinding Eye Disease
- Visual Improvement in Multiple RP11 Patients
- RP11 Clinical Trial Update - Amended
Later from PYC Therapeutics
- US FDA Grants Orphan Drug Designation to PYC Drug Candidate
- Interim Update on Progress in RP11 Repeat Dose Trials
- First ADOA Patient Dosed in Clinical Trial
- RP11 SRC Approves Dose Escalation to Final Patient Cohort
- Consolidation/Split - PYC
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics